PT2245018T - Processo para preparar bosentano - Google Patents

Processo para preparar bosentano

Info

Publication number
PT2245018T
PT2245018T PT97092829T PT09709282T PT2245018T PT 2245018 T PT2245018 T PT 2245018T PT 97092829 T PT97092829 T PT 97092829T PT 09709282 T PT09709282 T PT 09709282T PT 2245018 T PT2245018 T PT 2245018T
Authority
PT
Portugal
Prior art keywords
preparing bosentan
bosentan
preparing
Prior art date
Application number
PT97092829T
Other languages
English (en)
Portuguese (pt)
Inventor
Gaitonde Abhay
Manojkumar Bindu
Mekde Sandeep
Padalkar Vikas
Mande Hemant
Original Assignee
Generics Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40467334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2245018(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Generics Uk Ltd filed Critical Generics Uk Ltd
Publication of PT2245018T publication Critical patent/PT2245018T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT97092829T 2008-02-08 2009-02-06 Processo para preparar bosentano PT2245018T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN228KO2008 2008-02-08

Publications (1)

Publication Number Publication Date
PT2245018T true PT2245018T (pt) 2017-12-05

Family

ID=40467334

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97092829T PT2245018T (pt) 2008-02-08 2009-02-06 Processo para preparar bosentano

Country Status (10)

Country Link
US (1) US8785461B2 (cg-RX-API-DMAC10.html)
EP (1) EP2245018B1 (cg-RX-API-DMAC10.html)
JP (1) JP5683276B2 (cg-RX-API-DMAC10.html)
CN (1) CN101939301B (cg-RX-API-DMAC10.html)
AU (1) AU2009211159B2 (cg-RX-API-DMAC10.html)
CA (1) CA2712860C (cg-RX-API-DMAC10.html)
ES (1) ES2650247T3 (cg-RX-API-DMAC10.html)
NZ (1) NZ587793A (cg-RX-API-DMAC10.html)
PT (1) PT2245018T (cg-RX-API-DMAC10.html)
WO (1) WO2009098517A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
US8530488B2 (en) 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
JP2012507497A (ja) 2008-11-03 2012-03-29 ジェネリクス・（ユーケー）・リミテッド ボセンタンおよび関連物質のｈｐｌｃ分析方法、ならびに参照スタンダードまたはマーカーとしてのこれら物質の使用
WO2013098577A1 (en) * 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of bosentan
CN104487057A (zh) * 2012-05-11 2015-04-01 韩诺生物制药株式会社 波生坦控释口服制剂
CN112457259B (zh) * 2020-12-08 2024-02-20 重庆康乐制药有限公司 一种磺胺多辛的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
SI1535613T1 (sl) 1999-11-17 2010-12-31 Teva Pharma Postopek za pripravo polimorfne oblike atorvastatin kalcija
HUP0204069A3 (en) 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
PT1254121E (pt) 2000-01-25 2006-06-30 Hoffmann La Roche Preparacao de sulfonamidas
US6479692B1 (en) 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
AU2003209669A1 (en) 2003-02-25 2004-09-17 Hetero Drugs Limited Amorphous form of losartan potassium
US7872019B2 (en) 2003-03-12 2011-01-18 Cadila Healthcare Limited Polymorphs and amorphous form of (S)-(+)-clopidogrel bisulfate
WO2004087660A1 (en) 2003-04-02 2004-10-14 Hetero Drugs Limited A novel process for amorphous form of donepezil hydrochloride
AU2006248593B2 (en) 2005-05-17 2011-03-17 Actelion Pharmaceuticals Ltd. Dispersible bosertan tablet
US20080188663A1 (en) 2007-01-29 2008-08-07 Ashok Kumar Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I
BRPI0809171A2 (pt) 2007-04-02 2014-09-16 Auspex Pharmaceuticals Inc "composto, composição farmacêutica, método para tratamento,prevençõ ou melhora de um ou mais , sintomas de uma desordem mediada pela endotelina em um sujeito, método de inibição de ligação d euma endotelina a um receptor eta ou etb e método para modular a atividade mediada pelo receptor de endotelina"
WO2008135795A2 (en) 2007-05-08 2008-11-13 Generics [Uk] Limited Polymorphic forms of bosentan
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
EP2205591A1 (en) 2007-10-11 2010-07-14 Actavis Group PTC EHF Novel polymorphs of bosentan
US8530488B2 (en) 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
ATE530531T1 (de) * 2007-12-18 2011-11-15 Dipharma Francis Srl Verfahren zur herstellung von bosentan
WO2009095933A2 (en) 2008-01-10 2009-08-06 Msn Laboratories Limited Improved and novel process for the preparation of bosentan
US20110021547A1 (en) 2008-01-24 2011-01-27 Actavis Group Ptc Ehf Substantially Pure and a Stable Crystalline Form of Bosentan
WO2009112954A2 (en) 2008-03-13 2009-09-17 Actavis Group Ptc Ehf Processes for the preparation of bosentan and related compounds using novel intermediates
WO2009141167A1 (en) * 2008-05-23 2009-11-26 Synthon B.V. Bosentan salts
JP2012507497A (ja) 2008-11-03 2012-03-29 ジェネリクス・（ユーケー）・リミテッド ボセンタンおよび関連物質のｈｐｌｃ分析方法、ならびに参照スタンダードまたはマーカーとしてのこれら物質の使用
IT1393136B1 (it) 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan

Also Published As

Publication number Publication date
CN101939301B (zh) 2016-07-06
CN101939301A (zh) 2011-01-05
CA2712860A1 (en) 2009-08-13
AU2009211159A1 (en) 2009-08-13
US20110039871A1 (en) 2011-02-17
EP2245018A1 (en) 2010-11-03
CA2712860C (en) 2014-11-18
JP2011511054A (ja) 2011-04-07
NZ587793A (en) 2012-06-29
EP2245018B1 (en) 2017-08-30
AU2009211159B2 (en) 2013-02-07
US8785461B2 (en) 2014-07-22
WO2009098517A1 (en) 2009-08-13
JP5683276B2 (ja) 2015-03-11
ES2650247T3 (es) 2018-01-17

Similar Documents

Publication Publication Date Title
GB0813227D0 (en) Process for preparing membranes
EP2173736A4 (en) PROCESS FOR PREPARING VORICONAZOLE
IL214600A0 (en) Process for preparing substituted 2-nitrobiphenyls
GB0806422D0 (en) Process
GB0806419D0 (en) Process
IL220357A0 (en) Process for preparing substituted 1-o-acyl-2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranoses
ZA201102424B (en) Process for preparing 2-alkyl-3-aroyl-5-nitro-benzofurans
ZA201006842B (en) Process for preparing alkyl 2-alkoxymethylene-4,4-difluoro-3-oxobutyrates
GB0803669D0 (en) Process
GB0801580D0 (en) Process
GB0801209D0 (en) Process
IL218140A0 (en) Process for preparing 1-phenylpyrazoles
EP2328900A4 (en) PROCESS FOR PREPARING MORPHINAN-6 alpha-OLS
IL208514A0 (en) Process for preparing substituted biphenylanilides
GB0800875D0 (en) Process
HUE043359T2 (hu) Eljárás etil-benzol elõállítására
IL211307A0 (en) Process for preparing cinacalcet
PL2477964T3 (pl) Proces wytwarzania pochodnych alfa-karboksyamidu
IL207222A0 (en) Process for preparing hebivolol
ZA201106511B (en) Process for preparing antiviral compound
ZA201204825B (en) Process for preparing biocides
IL217584A (en) Process for the preparation of 4,2-dioxotetrahydroporan-3-carboxylates
ZA200907695B (en) Process for preparing dorzolam ide
GB0807161D0 (en) Process
GB0803960D0 (en) Process